Schöffski, P., & Kasper, B. (2018). Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’. Annals of oncology, 29(3), . https://doi.org/10.1093/annonc/mdx774
Chicago-Zitierstil (17. Ausg.)Schöffski, Patrick, und Bernd Kasper. "Activity and Safety of Crizotinib in Patients with Alveolar Soft Part Sarcoma with Rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) Phase II Trial 90101 ‘CREATE’." Annals of Oncology 29, no. 3 (2018). https://doi.org/10.1093/annonc/mdx774.
MLA-Zitierstil (9. Ausg.)Schöffski, Patrick, und Bernd Kasper. "Activity and Safety of Crizotinib in Patients with Alveolar Soft Part Sarcoma with Rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) Phase II Trial 90101 ‘CREATE’." Annals of Oncology, vol. 29, no. 3, 2018, https://doi.org/10.1093/annonc/mdx774.